Regulation FD Disclosure

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (the "Company") on December 29, 2025. The filing discloses a proposed business combination between the Company and Applied Digital Corporation ("Applied"). Upon closing, the combined entity will operate as ChronoScale Corporation, an accelerated compute platform focused on artificial intelligence workloads.

Key Financial Metrics

The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the Company or the proposed combined entity. This report focuses on the announcement of a transaction structure rather than financial performance data.

Material Changes and Transaction Structure

  • Proposed Transaction: The Company and Applied entered into an exclusive, non-binding term sheet for a business combination involving Applied's cloud computing business (Applied Digital Cloud).
  • Ownership Structure: Upon closing, Applied is expected to own approximately 97% of the combined company. Existing stockholders of Ekso Bionics are expected to hold approximately 3% of the outstanding shares, subject to dilution from any equity financing.
  • Operational Status: Both businesses will continue to operate independently until the transaction closes. The Company plans to explore strategic transactions for the possible sale of its current business.
  • Conditions: Closing is subject to due diligence, execution of binding documents, regulatory approvals, and stockholder approvals.

Guidance, Outlook, and Risks

Outlook and Next Steps: The parties expect to file a Registration Statement on Form S-4 or a standalone proxy statement with the SEC. A special meeting of stockholders will be held to vote on the transaction. No definitive agreement has been signed, and there is no assurance the transaction will be consummated.

Risks and Contingencies: The filing highlights significant risks, including the failure to negotiate definitive agreements, inability to sell the Company's existing business, integration difficulties, higher-than-anticipated transaction costs, and failure to obtain necessary regulatory or stockholder approvals. The filing contains forward-looking statements subject to uncertainties regarding future operating performance and financing plans.

Investor Verification Checklist

  • Verify the execution of a definitive binding agreement, as the current term sheet is non-binding.
  • Confirm the final ownership percentage of existing Ekso Bionics stockholders after any potential equity financing.
  • Monitor the status of the Company's plan to sell its current business operations.
  • Review the upcoming Proxy Statement/Prospectus (Form S-4) for detailed financial data and risk factors.
  • Track regulatory and stockholder approval timelines for the proposed transaction.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.